Patents by Inventor Eugen Uhlmann

Eugen Uhlmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050239733
    Abstract: Novel oligonucleotides having immune inhibitory effects, and methods for their use, are provided. The inhibitory oligonucleotides include those that specifically inhibit certain Toll-like receptors, including TLR7, TLR8, and TLR9. Certain of the immunoinhibitory oligonucleotides inhibit a combination of TLRs selected from TLR7, TLR8, and TLR9. Inhibitors of TLR9 are characterized by a 5? CC dinucleotide appropriately spaced upstream of a G-rich oligomer. Inhibitors of TLR8 include specific simple dinucleotides and oligonucleotides ending at their 3? termini with the specific dinucleotides. TLR7 inhibitors include oligonucleotides having a phosphorothioate backbone. Also provided are combinations and conjugates involving the inhibitory oligonucleotides of the invention and other agents, where the other agents include TLR agonists and antigens.
    Type: Application
    Filed: October 29, 2004
    Publication date: October 27, 2005
    Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.
    Inventors: Marion Jurk, Jorg Vollmer, Arthur Krieg, Eugen Uhlmann
  • Patent number: 6919441
    Abstract: The invention provides polyamide-oligonucleotide derivatives of the formula: F[(DNA-Li)q(PNA-Li)r(DNA-Li)s(PNA)t]xF?. In the formula, q, r, s, and t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s, and t is greater than or equal to 2; and x is 1 to 20. In the formula, DNA is a nucleic acid such as DNA or RNA or a known derivative thereof. Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, O, or S. PNA is a polyamide structure which contains at least one nucleotide base that is different from thymine. F and F? are end groups and/or are linked together by a covalent bond. The invention also provides physiologically tolerated salts of the above formula. The invention further provides a process for preparation of the polyamide-oligonucleotide derivatives of the invention as well as their use as pharmaceuticals, as gene probes, and as primers.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: July 19, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl
  • Publication number: 20050148017
    Abstract: Antisense oligonucleotides against tenascin for the treatment of vitiligo The invention relates to specific, optionally modified oligonucleotides having a length of up to 18 nucleotides, which correspond to sections of tenascin-coding sequences or can bind to these sequences, to their preparation and to the use thereof, for example for the specific inhibition of the expression of tenascin and for the production of pharmaceuticals which can be used for the treatment of vitiligo.
    Type: Application
    Filed: March 4, 2005
    Publication date: July 7, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Anuschirwan Peyman, Eugen Uhlmann, Caroline Weiser
  • Publication number: 20050130911
    Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.
    Type: Application
    Filed: September 27, 2004
    Publication date: June 16, 2005
    Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbH
    Inventors: Eugen Uhlmann, Jorg Vollmer, Arthur Krieg
  • Patent number: 6905820
    Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: June 14, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Patent number: 6878547
    Abstract: The invention relates to specific, optionally modified oligonucleotides with a length of up to 17 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: April 12, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Anuschirwan Peyman, Eugen Uhlmann, Caroline Weiser
  • Patent number: 6875589
    Abstract: A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: April 5, 2005
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Michael Dörschug, Paul Habermann, Gerhard Seipke, Eugen Uhlmann
  • Publication number: 20050059619
    Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.
    Type: Application
    Filed: August 19, 2003
    Publication date: March 17, 2005
    Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbH
    Inventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann, Marion Jurk, Grayson Lipford, Robert Rankin
  • Publication number: 20050026817
    Abstract: Polyamide-oligonucleotide derivatives of the formula F[(DNA-Li)q(PNA-Li)r(DNA-Li)s(PNA)t]xF? wherein q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t?2; x is 1 to 20; DNA is a nucleic acid such as DNA or RNA or a known derivative thereof; Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, O or S; PNA is a polyamide structure which contains at least one nucleotide base which is different from thymine; and F and F? are end groups and/or are linked together by a covalent bond, and the physiologically tolerated salts thereof, a process for their preparation and their use as pharmaceutical, as gene probe and as primer, are described.
    Type: Application
    Filed: September 10, 2004
    Publication date: February 3, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl
  • Publication number: 20050020523
    Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.
    Type: Application
    Filed: December 11, 2003
    Publication date: January 27, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Anuschirwan Peyman, David Will, Esther Chang, Kathleen Pirollo, Antonina Rait
  • Publication number: 20050009042
    Abstract: The present application relates to oligonucleotides which inhibit expression of the OB-RGRP protein and to uses thereof for preventing and/or treating leptin-related pathological conditions. It also relates to a method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor. This detection may be carried out by measuring the energy transfer between fusion proteins composed of these proteins and of energy-donor and -acceptor proteins.
    Type: Application
    Filed: February 9, 2004
    Publication date: January 13, 2005
    Applicants: Aventis Pharma S.A., Institut National De La Sante Et De La Racherche Medicale, Institut National De La Centre National De La Rechercher Scientifique
    Inventors: Ralf Jockers, Cyril Couturier, Eugen Uhlmann
  • Publication number: 20050009073
    Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.
    Type: Application
    Filed: June 2, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David Will
  • Publication number: 20040265885
    Abstract: The present invention relates to PNA derivatives which carry, at the N terminus of the PNA backbone, a phosphoryl radical. The phosphoryl radical can be, for example, a phosphate radical, or a substituted phosphoryl radical, with substituted phosphoryl derivatives carrying, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the abovementioned PNA derivatives and to their use as pharmaceuticals and diagnostic agents.
    Type: Application
    Filed: June 9, 2004
    Publication date: December 30, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Publication number: 20040171571
    Abstract: The invention relates to a class of CpG immunostimulatory oligonucleotides containing a 5′TCG motif or a CG at or near the 5′ end that are useful for stimulating an immune response.
    Type: Application
    Filed: December 11, 2003
    Publication date: September 2, 2004
    Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbH
    Inventors: Arthur M. Krieg, Marion Jurk, Jorg Vollmer, Eugen Uhlmann
  • Patent number: 6777544
    Abstract: The present invention relates to PNA derivatives which carry, at the N terminus of the PNA backbone, a phosphoryl radical. The phosphoryl radical can be, for example, a phosphate radical, or a substituted phosphoryl radical, with substituted phosphoryl derivatives carrying, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the abovementioned PNA derivatives and to their use as pharmaceuticals and diagnostic agents.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: August 17, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
  • Patent number: 6723706
    Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: April 20, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Anuschirwan Peyman, David William Will, Esther Chang, Kathleen Pirollo, Antonina Rait
  • Publication number: 20030203359
    Abstract: Polyamide-oligonucleotide derivatives of the formula
    Type: Application
    Filed: February 27, 2001
    Publication date: October 30, 2003
    Applicant: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl
  • Publication number: 20030176384
    Abstract: The present invention relates to an antisense oligonucleotide or a derivative thereof which has a sequence that corresponds to a part of a nucleic acid which encodes an integrin &agr;v subunit and which has the ability to induce apoptosis, the preparation and the use thereof.
    Type: Application
    Filed: November 6, 2002
    Publication date: September 18, 2003
    Inventors: Eugen Uhlmann, Anuschirwan Peyman, Anna Maria Teti, Ida Villanova
  • Publication number: 20030139585
    Abstract: The present invention relates to oligonucleotide derivatives which are at least partly double-stranded and which have a 2′5′-linked oligonucleotide residue on at least one 3′ end and to the use thereof for specific inhibition of gene expression.
    Type: Application
    Filed: July 11, 2002
    Publication date: July 24, 2003
    Inventors: Eugen Uhlmann, Jochen Huber, Niki Gunkel, Sandra Neumann
  • Publication number: 20030105052
    Abstract: The present invention relates to oligoribonucleotide derivatives which have a 2′5′-linked oligoribonucleotide residue without a 5′-phosphate residue on the 3′ end and to the use thereof for specific inhibition of gene expression.
    Type: Application
    Filed: July 11, 2002
    Publication date: June 5, 2003
    Inventors: Eugen Uhlmann, Jochen Huber, Niki Gunkel, Sandra Neumann